ZA202301801B - Inhibitors of sarm1 - Google Patents
Inhibitors of sarm1Info
- Publication number
- ZA202301801B ZA202301801B ZA2023/01801A ZA202301801A ZA202301801B ZA 202301801 B ZA202301801 B ZA 202301801B ZA 2023/01801 A ZA2023/01801 A ZA 2023/01801A ZA 202301801 A ZA202301801 A ZA 202301801A ZA 202301801 B ZA202301801 B ZA 202301801B
- Authority
- ZA
- South Africa
- Prior art keywords
- sarm1
- inhibitors
- treating
- present disclosure
- disclosure provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US202163142398P | 2021-01-27 | 2021-01-27 | |
| PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202301801B true ZA202301801B (en) | 2024-09-25 |
Family
ID=77775005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/01801A ZA202301801B (en) | 2020-08-24 | 2023-02-14 | Inhibitors of sarm1 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12043613B2 (OSRAM) |
| EP (1) | EP4200293A1 (OSRAM) |
| JP (2) | JP7349046B2 (OSRAM) |
| KR (1) | KR20230057396A (OSRAM) |
| AU (2) | AU2021333558C1 (OSRAM) |
| BR (1) | BR112023002575A2 (OSRAM) |
| CA (1) | CA3189181A1 (OSRAM) |
| CL (1) | CL2023000525A1 (OSRAM) |
| CO (1) | CO2023001975A2 (OSRAM) |
| CR (1) | CR20230113A (OSRAM) |
| DO (1) | DOP2023000038A (OSRAM) |
| EC (1) | ECSP23012981A (OSRAM) |
| IL (1) | IL300586A (OSRAM) |
| MX (1) | MX2023002256A (OSRAM) |
| PE (1) | PE20230737A1 (OSRAM) |
| TW (2) | TWI786777B (OSRAM) |
| WO (1) | WO2022046606A1 (OSRAM) |
| ZA (1) | ZA202301801B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| WO2022031736A1 (en) * | 2020-08-04 | 2022-02-10 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| US11945796B2 (en) | 2020-09-16 | 2024-04-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| JP2024528036A (ja) | 2021-07-28 | 2024-07-26 | ヌラ バイオ，インク． | Ｓａｒｍ１阻害剤としての置換ピリジン誘導体 |
| EP4558148A2 (en) * | 2022-07-21 | 2025-05-28 | Amylyx Pharmaceuticals Inc. | Oligonucleotide compositions and methods thereof |
| CN120457107A (zh) * | 2022-12-15 | 2025-08-08 | 维泰瑞隆有限公司 | Sarm1调节剂、其制备和用途 |
| CN121002009A (zh) | 2023-01-24 | 2025-11-21 | 达萨玛治疗公司 | 作为sarm1抑制剂的哒嗪类物 |
| WO2024222835A1 (en) * | 2023-04-27 | 2024-10-31 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| WO2025045746A1 (en) * | 2023-08-25 | 2025-03-06 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders |
| WO2025049184A1 (en) | 2023-08-25 | 2025-03-06 | Eli Lilly And Company | (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate |
| WO2025076017A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Carbamates for use as sarm1 inhibitors |
| WO2025076088A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Lactams for use as sarm1 inhibitors |
| WO2025157895A1 (en) | 2024-01-25 | 2025-07-31 | UCB Biopharma SRL | Pyrrolidinone derivatives |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999021555A2 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| NZ540161A (en) | 2002-10-30 | 2008-03-28 | Vertex Pharma | Compositions useful as inhibitors of rock and other protein kinases |
| AU2003300099A1 (en) | 2003-01-02 | 2004-07-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| DE602005020611D1 (de) | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| US8101770B2 (en) | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| KR101412943B1 (ko) | 2006-06-28 | 2014-06-26 | 아스카 세이야쿠 가부시키가이샤 | 피리딜이소옥사졸 유도체 |
| US20100105664A1 (en) | 2006-09-21 | 2010-04-29 | Richard Heng | Organic compounds |
| EA201000947A1 (ru) | 2007-12-20 | 2011-02-28 | Новартис Аг | Производные тиазола, применимые в качестве ингибиторов киназы pi3 |
| CN101939319A (zh) | 2007-12-20 | 2011-01-05 | 诺瓦提斯公司 | 联噻唑衍生物、它们的制备方法以及它们作为药物的用途 |
| TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
| US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| WO2012178022A2 (en) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Therapeutic applications targeting sarm1 |
| EP2914591B1 (en) | 2012-11-03 | 2017-10-11 | Boehringer Ingelheim International GmbH | Inhibitors of cytomegalovirus |
| US9695198B2 (en) | 2012-12-19 | 2017-07-04 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| EP3076789A4 (en) | 2013-12-04 | 2017-11-22 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| EP3500285B1 (en) | 2016-08-16 | 2022-04-20 | Henry Ford Health System | Compositions for the treatment of chemotherapy-induced neuropathic pain |
| WO2018057989A1 (en) | 2016-09-24 | 2018-03-29 | Washington University | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF |
| WO2018107056A1 (en) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels |
| WO2018114663A1 (de) | 2016-12-22 | 2018-06-28 | Bayer Cropscience Aktiengesellschaft | Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| BR112019012822A2 (pt) * | 2016-12-22 | 2019-11-26 | Bayer Ag | 1,2,4-tiadiazolilpirrolonas e 1,2,4-tiadiazolil-hidantoínas e sais das mesmas e uso das mesmas como herbicidas |
| CA3085460A1 (en) * | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CN112867489A (zh) * | 2018-06-07 | 2021-05-28 | 达萨玛治疗公司 | Sarm1抑制剂 |
| WO2019236884A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| JP2021527125A (ja) | 2018-06-07 | 2021-10-11 | ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｓａｒｍ１阻害剤 |
| US12084436B2 (en) | 2019-01-30 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3980011B1 (en) | 2019-06-06 | 2025-12-17 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US20220340546A1 (en) | 2019-06-14 | 2022-10-27 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| UY38795A (es) | 2019-07-22 | 2021-02-26 | Bayer Ag | 5-amino pirazoles y triazoles como plaguicidas |
| WO2021050913A1 (en) | 2019-09-12 | 2021-03-18 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| WO2021092240A1 (en) | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Mrgprx2 antagonists for the treatment of inflammatory disorders |
| MY206478A (en) | 2020-01-07 | 2024-12-18 | Disarm Therapeutics Inc | Inhibitors of sarm1 |
| CN115916764B (zh) | 2020-04-09 | 2024-09-20 | 达萨玛治疗公司 | 作为sarm1抑制剂的吲唑衍生物 |
| CN116075511B (zh) | 2020-04-09 | 2024-10-29 | 达萨玛治疗公司 | 作为sarm1抑制剂的稠合吡唑衍生物 |
| WO2022031736A1 (en) * | 2020-08-04 | 2022-02-10 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2021
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 KR KR1020237009643A patent/KR20230057396A/ko active Pending
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en not_active Ceased
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
-
2023
- 2023-02-14 ZA ZA2023/01801A patent/ZA202301801B/en unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP7756130B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373A1/en active Pending
- 2024-06-19 US US18/747,889 patent/US20240376083A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000038A (es) | 2023-03-15 |
| AU2021333558A1 (en) | 2023-03-02 |
| IL300586A (en) | 2023-04-01 |
| US20220056013A1 (en) | 2022-02-24 |
| US12043613B2 (en) | 2024-07-23 |
| CR20230113A (es) | 2023-04-14 |
| WO2022046606A1 (en) | 2022-03-03 |
| BR112023002575A2 (pt) | 2023-03-07 |
| TW202214597A (zh) | 2022-04-16 |
| AU2024203373A1 (en) | 2024-06-13 |
| JP2023535236A (ja) | 2023-08-16 |
| CA3189181A1 (en) | 2022-03-03 |
| AU2021333558C1 (en) | 2024-06-20 |
| TWI786777B (zh) | 2022-12-11 |
| JP7756130B2 (ja) | 2025-10-17 |
| EP4200293A1 (en) | 2023-06-28 |
| ECSP23012981A (es) | 2023-03-31 |
| PE20230737A1 (es) | 2023-05-03 |
| AU2021333558B2 (en) | 2024-02-22 |
| TW202530197A (zh) | 2025-08-01 |
| MX2023002256A (es) | 2023-03-17 |
| TW202334117A (zh) | 2023-09-01 |
| JP2024016014A (ja) | 2024-02-06 |
| KR20230057396A (ko) | 2023-04-28 |
| JP7349046B2 (ja) | 2023-09-21 |
| US20240376083A1 (en) | 2024-11-14 |
| CL2023000525A1 (es) | 2023-09-15 |
| CO2023001975A2 (es) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202301801B (en) | Inhibitors of sarm1 | |
| MY206478A (en) | Inhibitors of sarm1 | |
| WO2020252229A3 (en) | Inhibitors of sarm1 | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| MX2021003819A (es) | Moduladores de alfa-1 antitripsina. | |
| MX2022010944A (es) | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. | |
| CR20240296A (es) | Inhibidores parp1 | |
| MX2024004993A (es) | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2020247701A3 (en) | Inhibitors of sarm1 | |
| ZA202105742B (en) | Modulators of malat1 expression | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| MX2020010721A (es) | Moduladores de la expresion de ezh2. | |
| WO2021076817A3 (en) | Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2 | |
| MX2025003571A (es) | Inhibidores de tead y metodos de uso de los mismos | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof | |
| MX2024012789A (es) | Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa) | |
| WO2023034914A3 (en) | Methods for the prevention and treatment of synucleinopathies | |
| WO2022006377A3 (en) | Heterocyclic inhibitors of rho gtpases for the treatment of disease | |
| PH12022550572A1 (en) | Method for treating mood disorders | |
| MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. | |
| WO2025189072A8 (en) | Compositions and methods for inhibiting kinases | |
| MX2024000302A (es) | Nanoparticulas para tratamiento contra el cancer. |